RHEUMATOLOGICAL ASPECTS AND TREATMENTS OF COVID-19: Edited by Rebecca H. HabermanCoronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory diseaseSparks, Jeffrey A.a; Wallace, Zachary S.b; Robinson, Philip C.c,dAuthor Information aBrigham and Women's Hospital and Harvard Medical School bMassachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA cUniversity of Queensland School of Clinical Medicine, Faculty of Medicine dRoyal Brisbane & Women's Hospital, Metro North Hospital & Health Service, Herston, Queensland, Australia Correspondence to Philip C. Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women's Hospital, Herston, QLD 4006, Australia. Tel: +61 7 3646 7893; fax: +61 7 3646 1474; e-mail: [email protected] Current Opinion in Rheumatology: September 2021 - Volume 33 - Issue 5 - p 412-418 doi: 10.1097/BOR.0000000000000812 Buy Metrics Abstract Purpose of review Although the literature to date on COVID-19 outcomes in those with immune-mediated inflammatory disease has been largely reassuring there remain many unanswered questions. These include the impact of specific medications on outcomes and the antibody response after COVID-19 vaccination. Recent findings We summarized the current literature related to COVID-19 outcomes in immune-mediated inflammatory diseases in rheumatology, gastroenterology, dermatology, and neurology. Overall, we found either no difference or modest differences in risk for severe COVID-19 for people with immune-mediated diseases compared with the general population. When considering disease-specific factors, glucocorticoid use and underlying immune-mediated disease activity were generally associated with worse outcomes. Specific medications varied in associations: tumor necrosis factor inhibitors generally had lower odds for severe COVID-19 outcomes, whereas rituximab use generally had higher odds for severe outcomes. We also detailed the recent reports of antibody response to COVID-19 vaccination in people with immune-mediated inflammatory diseases. Summary Investigations of immune-mediated inflammatory diseases across several organ systems have offered important insight into the COVID-19 disease course. Overall, these studies have provided reassurance to patients and clinicians while also identifying groups who may be at higher risk for poor outcomes. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.